---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-22-004019"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:03:35.584614+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Chemomab appoints Matthew Frankel as CMO & VP Drug Development, effective Nov 14

## Summary
- Dr. Frankel will receive annual base salary of $450,000 and bonus potential of 45% of base.
- He receives a signing bonus of $200,000, payable in two $100,000 installments within 60 and 120 days.
- Granted options to purchase 125,000 ADRs, vesting over four years (25% on first anniversary, remainder monthly).
- Frankel previously led clinical development at Boehringer Ingelheim, Novartis, Sandoz, and Reata Pharmaceuticals.
- Interim CMO Dave Weiner will stay on as Senior Advisor.

## SEC filing metadata
- accession: 0001178913-22-004019
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/0001178913-22-004019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-22-004019
- JSON: https://secwatch.observer/filing/0001178913-22-004019.json
- Plain text: https://secwatch.observer/filing/0001178913-22-004019.txt

## Key facts
- Executive change
  Dr. Matthew B. Frankel was appointed as Chief Medical Officer & VP, Drug Development at Chemomab Therapeutics Ltd..
  - Action: appointed
  - Role: Chief Medical Officer & VP, Drug Development
  source text: On November 14, 2022, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Matthew B. Frankel as Chief Medical Officer & VP, Drug Development of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891322004019/0001178913-22-004019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.